Systemic HypertensionSystemic Hypertension2075-082X2542-2189Intermedservice Ltd6511610.26442/2075082X.2021.1.200736Research ArticleAspects of efficacy, safety and adherence to antihypertensive therapy with single pill combinations of valsartan, amlodipine and hydrochlorothiazide (Vamloset® and Co-Vamloset) in patients with 2 and 3 grade of arterial hypertension in the Russian clinical study VICTORY IIChazovaIrina E.<p>D. Sci. (Med.), Prof., Acad. RAS, Myasnikov Institute of Clinical Cardiology, National Medical Research Center of Cardiology</p>c34h@yandex.ruhttps://orcid.org/0000-0002-9822-4357MartynyukTamila V.<p>D. Sci. (Med.), Prof., Myasnikov Institute of Clinical Cardiology, National Medical Research Center for Cardiology, Pirogov Russian National Research Medical University</p>trukhiniv@mail.ruRodnenkovOleg V.<p>Cand. Sci. (Med.), Myasnikov Institute of Clinical Cardiology, National Medical Research Center for Cardiology</p>c34h@yandex.ruGorievaShurat B.<p>Cand. Sci. (Med.), Myasnikov Institute of Clinical Cardiology, National Medical Research Center for Cardiology</p>c34h@yandex.ruRogozaAnatolii N.<p>D. Sci. (Biol.), Prof., Myasnikov Institute of Clinical Cardiology, National Medical Research Center for Cardiology</p>c34h@yandex.ruArkhipovMikhail V.<p>D. Sci. (Med.), Prof., Ural State Medical University</p>c34h@yandex.ruGrinshteinYury I.<p>D. Sci. (Med.), Prof., Voino-Yasenetski Krasnoyarsk State Medical University</p>c34h@yandex.ruOstroumovaOlga D.<p>D. Sci. (Med.), Prof., Russian Medical Academy of Continuous Professional Education</p>c34h@yandex.ruhttps://orcid.org/0000-0002-0795-8225GalyavichAlbert S.<p>D. Sci. (Med.), Prof., Kazan State Medical University</p>c34h@yandex.ruhttps://orcid.org/0000-0002-4510-6197Rotar’Oxana P.<p>D. Sci. (Med.), Almazov National Medical Research Centre</p>c34h@yandex.ruKhaishevaLarisa A.<p>D. Sci. (Med.), Prof., Rostov State Medical University</p>c34h@yandex.ruKamenevaTatiana R.<p>Cand. Sci. (Med.), Konchalovskiy City Clinical Hospital</p>c34h@yandex.ruMyasnikov Institute of Clinical Cardiology, National Medical Research Center for CardiologyPirogov Russian National Research Medical UniversityUral State Medical UniversityVoino-Yasenetski Krasnoyarsk State Medical UniversityRussian Medical Academy of Continuous Professional EducationKazan State Medical UniversityAlmazov National Medical Research CenterRostov State Medical UniversityKonchalovskii City Clinical Hospital1503202118150621504202115042021Copyright © 2021, Consilium Medicum2021<p>Aim. To assess the efficacy and safety of Vamloset (amlodipine/valsartan 5/80, 5/160, 10/160 mg) and Co-Vamloset (amlodipine/valsartan/hydrochlorothiazide 10/160/12.5, 10/160/25 mg) in achieving the target levels of blood pressure (BP) in patients with stage 23 arterial hypertension (AH). The article discusses indicators affecting adherence to antihypertensive therapy (AHT).</p>
<p>Material and methods. The VICTORY II Russian study in 8 clinical centers of the Russian Federation included 103 patients over 18 years of age with stage 23 essential AH (who havent been previously treated and have office systolic BP160 mm Hg and/or diastolic BP100 mm Hg or who havent reached the target office blood pressure with mono- or double AHT). The Full Analysis Set (FAS) for efficacy analysis included 99 patients, a FAS population with the restoration of data missed using Last Observation Carried Forward. The SF-36 questionnaire for assessing the quality of life, the effect on erectile function in men, the convenience of current therapy from the point of view of patients were analyzed after 16 weeks of treatment. The Per Protocol (PP) population included 80 patients completing the study without major protocol deviations to assess the primary parameters of efficacy. All patients with stage 2 hypertension were prescribed Vamloset (amlodipine/valsartan 5/80 mg), with stage 3 hypertension amlodipine/valsartan 5/160 mg. Dose titration of Vamloset and Co-Vamloset (LLC Krka-RUS) was carried out every 4 weeks according to the AHT schemes.</p>
<p>Results. The studys active phase included 100 patients aged 59.510.9 years (women 59%) with AH duration of 83.48.4 months; 83% of patients received AHT prior inclusion in the study. In the PP population, 16 week- AHT with Vamloset or Co-Vamloset allowed reaching the target BP in 90.0% of patients (95% confidence interval [CI] 81.295.6). Overall clinical efficacy was achieved in 98.8% of patients (95% CI 93.2100.0). All treatment regimens were characterized by high patient compliance. In the total group, 50% of patients rated their AHT as more convenient than they had previously used; of them, in the stage 2 AH group 47.8%, in the stage 3 AH group 53.3%. Metabolic neutrality with regard to at least one indicator was observed in 100% of patients, with regard to 6 indicators in 43.9% [33.9; 54.9]. For all 98 patients included in the analysis, changes in all SF-36 scales, except for physical functioning (p=0.339), were statistically significant (p0.05). The effect of AHT on erectile function was rated as positive in 51.3% of men. Good tolerance data are consistent with the established drug safety profile.</p>
<p>Conclusion. In the VICTORY II study, high antihypertensive efficacy and an improvement in a set of indicators of optimal adherence to AHT by Vamloset and Co-Vamloset within 16 weeks were proved in patients with stage 23 AH. Patients high rating for quality improvement in the quality of life, safety of therapy and ease of use ensured optimal compliance of Vamloset and Co-Vamloset therapy throughout the study.</p>VICTORY IIRussian clinical studyadherencearterial hypertensionfixed dose combinationssingle pill combinationsvalsartanamlodipinehydrochlorothiazideVamloset®Co-VamlosetVICTORY IIроссийское клиническое исследованиеприверженностьартериальная гипертонияфиксированные комбинациивалсартанамлодипингидрохлоротиазидВамлосет®Ко-Вамлосет[Чазова И.Е., Жернакова Ю.В. от имени экспертов. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Системные гипертензии. 2019; 16 (1): 6–31 [Chazova IE, Zhernakova YuV on behalf of the experts. Clinical guidelines. Diagnosis and treatment of arterial hypertension. Systemic Hypertension. 2019; 16 (1): 6–31 (in Russian)].][Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J 2018; 39: 3021–104.][Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension 2020; 75: 1334–57.][Mills KT, Bundy JD, Kelly TN, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation 2016; 134: 441–50.][Non-Communicable Disease Risk Factor Collaboration. Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants. Lancet 2017; 389: 37–55.][Global Burden of Disease Risk Factor Collaborators. Global, regional and national comparative risk assessment of 84 behavioral, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018; 392: 1923–94.][Corrao G, Parodi A, Nicotra F, et al. Better compliance to antihypertensive medications reduces cardiovascular risk. J Hypertens 2011; 29: 610–8.][Tomaszewski M, White C, Patel P, et al. High rates of non-adherence to antihypertensive treatment revealed by high-performanceliquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis. Heart 2014; 100: 855–86.][Mazzaglia G, Ambrosioni E, Alacqua M, et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation 2009; 120: 1598–605.][Gupta P, Patel P, Strauch B, et al. Risk factors for nonadherence to antihypertensive treatment. Hypertension 2017; 69: 1113–20.][Wei FF, Zhang ZY, Huang QF, Staessen JA. Diagnosis and management of resistant hypertension: state of the art. Nat Rev Nephrol 2018; 14: 428–41.][Gupta P, Patel P, Horne R, et al. How to screen for non-adherence to antihypertensive therapy. Curr Hypertens Rep 2016; 18: 89.][Abegaz TM, Shehab A, Gebreyohannes EA, et al. Nonadherence to antihypertensive drugs: a systematic review and meta-analysis. Medicine 2017; 96: e5641.][Чукаева И.И. Комплаентность и возможности полнодозовых комбинированных гипотензивных препаратов. Артериальная гипертензия. 2012; 18 (1): 46–51 [Chukaeva II. Komplaentnost’ i vozmozhnosti polnodozovykh kombinirovannykh gipotenzivnykh preparatov. Arterial’naia gipertenziia. 2012; 18 (1): 46–51 (in Russian)].][Hill M, Houston N. Adherence to antihypertensive therapy. 2007; p. 390–2.][Geldsetzer P, Manne-Goehler J, Marcus MЕ, et al. The state of hypertension care in 44 low-income and middle-income countries: a cross-sectional study of nationally representative individual-level data from 1.1 million adults. Lancet 2019; 394: 652–62.][Non-communicable Disease Risk Factor Collaboration . Long-term and recent trends in hypertension awareness, treatment, and control in 12 high-income countries: an analysis of 123 nationally representative surveys. Lancet 2019; 394: 639–51.][Lewington S, Clarke R, Qizilbash N, et al. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903–13.][Mancia G. COVID-19, hypertension, and RAAS blockers: the BRACE-CORONA trial. Cardiovasc Res 2020; 116 (14): e198–e199.][Jin J, Sklar GE, Oh VMS et al. Factors affecting therapeutic compliance: A review from the patient`s perspective. Ther Clin Risk Manag 2008; 4 (1): 269–86.][Рекомендации ESH/ESC 2013 г. по лечению артериальной гипертонии. Системные гипертензии. 2013; 10 (4): 5–27 [2013 ESH/ESC Guidelines for the management of arterial hypertension. Systemic Hypertension. 2013; 10 (4): 5–27 (in Russian)].][Matsuzaki M, Ogihara T, Umemoto S, et al. Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial Group. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial. J Hypertension. 2011; 29: 1649–59.][Чазова И.Е., Мартынюк Т.В., Accetto R., и др. Итоги международного клинического исследования VICTORY: эффективность и безопасность антигипертензивной монотерапии валсартаном (Вальсакор®) и его фиксированной комбинации с гидрохлоротиазидом (Вальсакор® Н) у пациентов с артериальной гипертонией 1–2-й степени в рутинной клинической практике. Системные гипертензии. 2017; 14 (2): 80–9 [Chazova IE, Martynyuk TV, Accetto R, et al. The results of the international clinical study VICTORY: efficacy and safety of antihypertensive monotherapy with valsartan (Valsacor®) and its fixed combination with hydrochlorothiazide (Valsacor® H) in routine clinical practice in patients with grade 1 and grade 2 hypertension. Systemic Hypertension. 2017; 14 (2): 80–9 (in Russian)].][Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004; 363: 2049–51.][Чазова И.Е., Мартынюк Т.В., Accetto R., и др. Влияние антигипертензивной терапии валсартаном и его фиксированной комбинации с гидрохлоротиазидом на скорость пульсовой волны и центральное артериальное давление у пациентов с артериальной гипертонией 1–2-й степени по результатам международного клинического исследования VICTORY. Системные гипертензии. 2018; 15 (2): 6–13 [Chazova IE, Martynyuk TV, Accetto R, et al. The influence of antihypertensive therapy with valsartan and fixed combination with hydrochlorothiazide use on pulse-wave velocity and central arterial pressure in patients with arterial hypertension of 1–2 grades in international VICTORY clinical trial. Systemic Hypertension. 2018; 15 (2): 6–13 (in Russian)].][Чазова И.Е., Мартынюк Т.В., Родненков О.В., и др. Первые результаты российского многоцентрового проспективного клинического исследования VICTORY II: эффективность и безопасность препаратов Вамлосет® и Ко-Вамлосет у пациентов с артериальной гипертонией 2 и 3-й степени. Системные гипертензии. 2020; 17 (2): 36–47 [Chazova IE, Martynyuk TV, Rodnenkov OV, et al. First results of Russian multicenter prospective clinical study VICTORY II: Vamloset® and Co-Vamloset effectiveness and safety in patients with stage 2 and 3 arterial hypertension. Systemic Hypertension. 2020; 17 (2): 36–47 (in Russian)].][Hagendorff A, Freytag S, Müller A, et al. Pill Burden in Hypertensive Patients Treated with Single-Pill Combination Therapy – An Observational Study. Adv Ther 2013; 30 (4): 406–19.][Отчет о клиническом исследовании «Эффективность и безопасность препаратов Вамлосет® (амлодипин/валсартан, 5/80 мг, 5/160 мг, 10/160 мг), таблетки, покрытые пленочной оболочкой, производства ООО «КРКА-РУС», Россия и Ко-Вамлосет (амлодипин/валсартан/гидрохлоротиазид, 10/160/12,5 мг, 10/160/25 мг), таблетки, покрытые пленочной оболочкой, производства ООО «КРКА-РУС», Россия» у пациентов с АГ 2-й и 3-й степени. Финальный отчет. ООО «КРКА-РУС», 2019 [Otchet o klinicheskom issledovanii «Effektivnost’ i bezopasnost’ preparatov Vamloset® (amlodipin/valsartan, 5/80 mg, 5/160 mg, 10/160 mg), tabletki, pokrytye plenochnoi obolochkoi, proizvodstva OOO «KRKA-RUS’, Rossiia i Co-Vamloset (amlodipin/valsartan/gidrokhlorotiazid, 10/160/12.5 mg, 10/160/25 mg), tabletki, pokrytye plenochnoi obolochkoi, proizvodstva OOO «KRKA-RUS», Rossiia» u patsientov s AG 2-i i 3-i stepeni. Final’nyi otchet. OOO «KRKA-RUS’, 2019 (in Russian)].][Accetto R, Chazova I, Sirenko Y, et al. The results of the international study “VICTORY”. Presented at XVIth Ukrainian National Congress of Cardiology by Sirenko M, Radchenko G on behalf of investigators. 23–25.09.2015, Kiev, Ukraine.][The efficacy and safety of valsartan and combination of valsartan and hydrochlorothiazide in the treatment of patients with mild to moderate arterial hypertension – VICTORY. Final report. Data on file. Krka d.d., Novo mesto, Slovenia, 2015.]